Literature DB >> 32663354

Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus.

Xiao-Hui Wang1,2, Bing Liao3, Wen-Jie Hu1, Cai-Xue Tu4, Cai-Ling Xiang5, Sheng-Hua Hao4, Xian-Hai Mao5, Xiao-Ming Qiu6, Xiao-Jun Yang6, Xiao Yue1, Ming Kuang1, Bao-Gang Peng1, Shao-Qiang Li1.   

Abstract

BACKGROUND: The predictive model of postsurgical recurrence for solitary early hepatocellular carcinoma (SE-HCC) is not well established. The aim of this study was to develop a novel model for prediction of postsurgical recurrence and survival for patients with hepatitis B virus (HBV)-related SE-HCC ≤10 cm. PATIENTS AND METHODS: Data from 1,081 patients with HBV-related SE-HCC ≤10 cm who underwent curative liver resection from 2003 to 2016 in our center were collected retrospectively and randomly divided into the derivation cohort (n = 811) and the internal validation cohort (n = 270). Eight hundred twenty-three patients selected from another four tertiary hospitals served as the external validation cohort. Postsurgical recurrence-free survival (RFS) and overall survival (OS) predictive nomograms were generated. The discriminatory accuracies of the nomograms were compared with six conventional hepatocellular carcinoma (HCC) staging systems.
RESULTS: Tumor size, differentiation, microscopic vascular invasion, preoperative α-fetoprotein, neutrophil-to-lymphocyte ratio, albumin-to-bilirubin ratio, and blood transfusion were identified as the risk factors associated with RFS and OS. RFS and OS predictive nomograms based on these seven variables were generated. The C-index was 0.83 (95% confidence interval [CI], 0.79-0.87) for the RFS-nomogram and 0.87 (95% CI, 0.83-0.91) for the OS-nomogram. Calibration curves showed good agreement between actual observation and nomogram prediction. Both C-indices of the two nomograms were substantially higher than those of the six conventional HCC staging systems (0.54-0.74 for RFS; 0.58-0.76 for OS) and those of HCC nomograms reported in literature.
CONCLUSION: The novel nomograms were shown to be accurate at predicting postoperative recurrence and OS for patients with HBV-related SE-HCC ≤10 cm after curative liver resection. IMPLICATIONS FOR PRACTICE: This multicenter study proposed recurrence or mortality predictive nomograms for patients with hepatitis B virus-related solitary early hepatocellular carcinoma ≤10 cm after curative liver resection. A close postsurgical surveillance protocol and adjuvant therapy should be considered for patients at high risk of recurrence.
© 2020 AlphaMed Press.

Entities:  

Keywords:  Early stage; Hepatocellular carcinoma; Nomogram; Prognosis

Mesh:

Year:  2020        PMID: 32663354      PMCID: PMC7543242          DOI: 10.1634/theoncologist.2019-0766

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159            Impact factor:   5.837


  49 in total

1.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

Authors:  E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema
Journal:  J Clin Epidemiol       Date:  2001-08       Impact factor: 6.437

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

3.  Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection.

Authors:  Tianbo Yang; Jiye Zhu; Lei Zhao; Kangye Mai; Jiazhou Ye; Shan Huang; Yinnong Zhao
Journal:  J Surg Oncol       Date:  2017-01-27       Impact factor: 3.454

Review 4.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

5.  Validated nomogram for the prediction of disease-free survival after hepatectomy for hepatocellular carcinoma within the Milan criteria: individualizing a surveillance strategy.

Authors:  Ka Wing Ma; Wong Hoi She; Tan To Cheung; Albert Chi Yan Chan; Wing Chiu Dai; James Yan Yue Fung; Chung Mau Lo; Kenneth Siu Ho Chok
Journal:  Surg Today       Date:  2019-01-14       Impact factor: 2.549

6.  Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas.

Authors:  Pinghua Yang; Jiliang Qiu; Jun Li; Dong Wu; Xuying Wan; Wan Yee Lau; Yunfei Yuan; Feng Shen
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

7.  The significance of classifying microvascular invasion in patients with hepatocellular carcinoma.

Authors:  Shuji Sumie; Osamu Nakashima; Koji Okuda; Ryoko Kuromatsu; Atsushi Kawaguchi; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Maisa Hori; Tatsuyuki Kakuma; Takuji Torimura; Michio Sata
Journal:  Ann Surg Oncol       Date:  2013-11-20       Impact factor: 5.344

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 9.  Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer.

Authors:  Ryan A Hlady; Keith D Robertson
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

10.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Authors:  Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640

View more
  6 in total

1.  Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis.

Authors:  Huanhuan Cui; Yuechao Yang; Mingtao Feng; Yang Gao; Liangdong Li; Wenjing Tu; Xin Chen; Bin Hao; Sen Li; Deheng Li; Lei Chen; Changshuai Zhou; Yiqun Cao
Journal:  Transl Oncol       Date:  2022-05-19       Impact factor: 4.803

2.  A Nomogram to Predict Lifestyle Factors for Recurrence of Large-Vessel Ischemic Stroke.

Authors:  Zhi-Xin Huang; Shumin Yuan; Dongshi Li; Hong Hao; Zhenguo Liu; Jianguo Lin
Journal:  Risk Manag Healthc Policy       Date:  2021-02-02

3.  A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE.

Authors:  Shuyang Hu; Wei Gan; Liang Qiao; Cheng Ye; Demin Wu; Boyi Liao; Xiaoyu Yang; Xiaoqing Jiang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 4.  Advances in postoperative adjuvant therapy for primary liver cancer.

Authors:  Zhi-Ming Zeng; Ning Mo; Jie Zeng; Fu-Chao Ma; Yan-Feng Jiang; Hua-Sheng Huang; Xi-Wen Liao; Guang-Zhi Zhu; Jie Ma; Tao Peng
Journal:  World J Gastrointest Oncol       Date:  2022-09-15

Review 5.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

6.  Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective.

Authors:  Xia Zheng; Bin Ye; Yudong Gou; Zixiong Li; Chao Chen; Feng Liao; Xiufeng Liu; Shukui Qin
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.